1. Home
  2. ENSC vs ORIS Comparison

ENSC vs ORIS Comparison

Compare ENSC & ORIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENSC
  • ORIS
  • Stock Information
  • Founded
  • ENSC 2003
  • ORIS 2014
  • Country
  • ENSC United States
  • ORIS China
  • Employees
  • ENSC N/A
  • ORIS N/A
  • Industry
  • ENSC Biotechnology: Pharmaceutical Preparations
  • ORIS Farming/Seeds/Milling
  • Sector
  • ENSC Health Care
  • ORIS Consumer Staples
  • Exchange
  • ENSC Nasdaq
  • ORIS Nasdaq
  • Market Cap
  • ENSC 6.4M
  • ORIS 5.3M
  • IPO Year
  • ENSC N/A
  • ORIS 2024
  • Fundamental
  • Price
  • ENSC $2.10
  • ORIS $0.14
  • Analyst Decision
  • ENSC
  • ORIS
  • Analyst Count
  • ENSC 0
  • ORIS 0
  • Target Price
  • ENSC N/A
  • ORIS N/A
  • AVG Volume (30 Days)
  • ENSC 54.6K
  • ORIS 17.4M
  • Earning Date
  • ENSC 11-11-2025
  • ORIS 01-01-0001
  • Dividend Yield
  • ENSC N/A
  • ORIS N/A
  • EPS Growth
  • ENSC N/A
  • ORIS N/A
  • EPS
  • ENSC N/A
  • ORIS 0.17
  • Revenue
  • ENSC $7,413,722.00
  • ORIS $15,014,000.00
  • Revenue This Year
  • ENSC N/A
  • ORIS N/A
  • Revenue Next Year
  • ENSC $1,354.55
  • ORIS N/A
  • P/E Ratio
  • ENSC N/A
  • ORIS $0.83
  • Revenue Growth
  • ENSC 415.58
  • ORIS N/A
  • 52 Week Low
  • ENSC $1.62
  • ORIS $0.08
  • 52 Week High
  • ENSC $14.67
  • ORIS $56.01
  • Technical
  • Relative Strength Index (RSI)
  • ENSC 48.61
  • ORIS 46.56
  • Support Level
  • ENSC $2.02
  • ORIS $0.11
  • Resistance Level
  • ENSC $2.19
  • ORIS $0.20
  • Average True Range (ATR)
  • ENSC 0.10
  • ORIS 0.02
  • MACD
  • ENSC 0.00
  • ORIS 0.01
  • Stochastic Oscillator
  • ENSC 41.45
  • ORIS 34.85

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

About ORIS Oriental Rise Holdings Limited Ordinary Shares

Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).

Share on Social Networks: